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Abstract
Introduction: The aim of this analysis was to describe comprehensively the cross-sectional and longitudinal
patterns of analgesic and nutraceutical medication use for knee osteoarthritis (OA) in a contemporary US cohort
and to investigate associated demographic and clinical factors.
Methods: Baseline, 12, 24 and 36 month data were obtained retrospectively from the National Institutes of Health
Osteoarthritis Initiative. Participants had symptomatic radiographic knee OA. Multiple binary logistic regression
models identified characteristics independently associated with the use of analgesics or nutraceuticals.
Results: We included 987 subjects (55.9% female, mean age 61.5 years, 71.0% white). At baseline, 68.2% reported
frequent use of a conventional analgesic or nutraceutical for joint pain (for more than half of the previous month).
Non-prescription non-steroidal anti-inflammatory drugs (NSAIDs) were the most frequently reported medications
(26.8%), even in those more than 75-years old. Multiple conventional analgesics were used by 11.9%. Frequent
analgesic use was more likely in women (odds ratio (OR) 1.8 (95% confidence interval (CI) 1.3 to 2.3)) and people
with more pain (moderate 1.7 (1.2 to 2.4); severe 3.1 (2.1 to 4.7)); nutraceutical use was less likely in non-whites (0.4
(0.3 to 0.6)), those more than 74-years old (0.6 (0.3 to 0.9)) and those with comorbidities (0.6 (0.5 to 0.9)) and more
likely in people with Kellgren-Lawrence (KL) grade 4 (2.2 (1.5 to 3.3)). Overall there was no change in the
proportion of participants frequently using prescription or over the counter (OTC) analgesics at 36 months,
although most people had changed medication type; of those using a traditional analgesic at baseline
approximately one third were still using the same type at 36 months (ranging from 26.2% of baseline prescription
NSAID users to 40.6% of baseline acetaminophen users). All participants reporting baseline analgesic use also
reported 36 month analgesic use. Female participants (OR 95% CI 1.2 to 3.2, P = 0.009), those with high body mass
index (1.2 to 4.8, P = 0.010) and those with moderate (1.6 to 2.6, P = 0.090) or severe (1.8 to 12.0, P = 0.002)
baseline pain were more likely to use pain medication during the 36 month follow-up period; participants more
than 75-years old were less likely (0.2 to 1.0, P = 0.053).
Conclusions: Most people with knee OA used pharmacological therapies frequently, and use appeared to be
according to American College of Rheumatology recommendations. Change in medication type used was
common. Persistent non-prescription NSAID use in older people is an area of concern.
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Introduction
Osteoarthritis (OA) has a profound impact on overall
quality of life [1-4]. In the United States, OA is the most
prevalent joint disease and the leading cause of chronic
disability [5]; 26.9 million people 25-years-old or over have
clinical OA of at least one joint [6], costing an estimated
$89.1 billion per year [7]. Poorer outcome in terms of pain
and function has been linked to risk factors such as female
sex, high body mass index (BMI) and African-American
ethnicity [8-11].
Various treatment options have been proven effective in
reducing OA pain [12] and current guidelines for the con-
temporary management of hip or knee OA recommend
the use of both non-pharmacological and pharmacological
therapies [13-16]. In addition to traditional therapies,
there are increasing reports of the use of nutraceuticals
(defined as ‘foodstuffs which provide health benefits in
addition to their basic nutritional value’) for the treatment
of OA, although current guidelines do not recommend
them [14,15]. Despite a marked increase in nutraceutical
use for all indications over the past decade [17], few stu-
dies have investigated their use by people with OA.
A number of studies have examined how specific
classes of therapies are used by people with OA and the
relationship of use with various demographic factors,
including age, gender and race. These studies suggest, for
example, that African-Americans are prescribed fewer
analgesics [18-21], opioid use declines in older patients
[21] and women use more analgesics and a higher num-
ber of medications [22]. However, few recent studies
have comprehensively examined the overall pattern of
use and frequency with which OA pharmacological
therapies are prescribed and factors associated with their
use. In particular, there has been little research regarding
the use of nutraceuticals or the use of combinations of
therapy by individuals. Identification of factors associated
with use of pharmacological therapy is the first step
toward improving OA therapy for these populations.
Because the prevalence of knee OA increases with age,
the efficacy and safety/tolerability of prescribed drugs
must be carefully considered; more than 90% of patients
with OA are at increased gastrointestinal (GI) and/or car-
diovascular (CV) risk. Use of NSAIDs and COX-2 inhibi-
tors (coxibs) has been associated with a range of increased
CV and GI complications [23-26] and are not recom-
mended in those more than 75-years-old [15]. A recent
study of non-steroidal anti-inflammatory drug (NSAID)
prescription suggested that in more than half of OA
patients, NSAID prescription was not in accordance with
these guidelines [27]. Examining medication use in this
age group, where treatment options are more limited, is,
therefore, particularly pertinent.
The aim of this study was, therefore, to comprehensively
describe analgesic and nutraceutical medication use at
baseline and over time in a contemporary US cohort and
its relationship with age, sex, race, BMI, co-morbidities,
Kellgren-Lawrence (KL) grade and severity of pain.
Methods
Data used in the preparation of this article were obtained
from the Osteoarthritis Initiative (OAI) database, a pub-
licly available multi-centre population-based observational
cohort study of knee OA which is available for public
access [28]. Specific datasets used are detailed in Addi-
tional File 1, Methods. The OAI cohort is composed of
three groups, the Progression (n = 1,390) and Incidence
(n = 3,285) subcohorts and the Non-exposed Control
group (n = 122). The Progression subcohort consists of
individuals (age 45 to 79 years) with symptomatic tibiofe-
moral knee OA in at least one knee at baseline and was
the focus of the current study. Symptomatic tibiofemoral
knee OA is defined in the OAI as 1) participant report of
frequent knee symptoms (defined as aching/pain/stiffness
in or around the knee) on most days for ≥1 month during
the past 12 months and 2) radiographic evidence of tibio-
femoral knee OA defined as the presence of an Osteoar-
thritis Research Society International (OARSI) atlas
osteophyte grade 1 to 3, equivalent to Kellgren and Lawr-
ence (KL grade) ≥2, on fixed flexion radiograph based on
the individual clinic readings. Follow-up data are currently
available at 12, 24 and 36 months. For this analysis we
used baseline and 36 months data, except for the analysis
of frequent use of medication for pain, aching or stiffness
at any point over 36 months of follow-up, for which the
12 and 24 month data were also used.
Baseline assessment included age, sex and ethnicity.
Co-morbid medical conditions were assessed by a self-
reported version of the Charlson comorbidity index [29].
Self-reported global knee pain severity during the past
30 days was assessed using a 0 to 10 numerical rating
scale (NRS). An inventory of all prescription medication
used in the past 30 days was collected at the baseline
visit. Subjects were asked to bring in or identify all
prescription medication taken in the preceding 30 days;
subjects were not asked to bring in over-the-counter
(OTC) medications. Use of prescription gastro-protective
agents was extracted from this medication inventory.
Participants were also asked whether they had used
prescription analgesics in the last 30 days, and whether
they had used classes of prescription or OTC medica-
tions (acetaminophen, NSAIDs, coxibs, opioids) and/or
nutraceuticals (glucosamine, chondroitin, methylsulfonyl-
methane (MSM), doxycycline or S-adenosylmethionine
(SAMe)) for more than half of the days of the previous
month, specifically for pain, aching or stiffness in their
knee (classed as frequent use). The design of the OAI
medication questionnaire allowed us to distinguish
between prescription and OTC NSAID use and these
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were considered different ‘types’ of analgesic, but it was
not possible to determine whether or not acetaminophen
had been prescribed.
Further details on the specific databases accessed dur-
ing this study and the OAI exclusion criteria are provided
in Additional File 1, Methods. We excluded subjects who
had knee replacements because they could have been tak-
ing medication for pain due to knee replacement. We
also excluded those with missing data due to drop out,
incomplete patient-reported arthritis pain medication
data or incomplete baseline demographic and/or clinical
data.
Statistical analysis was performed using SPSS version
19.0.2. Baseline characteristics evaluated for their associa-
tion with medication use included sex; race (white, non-
white, the latter category comprising African-Americans,
Asians and ‘non-white: other’); age (grouped into three
bands according to risk factors for medication use: under
65 years, 65 to 74 years and over 74 years); severity of
pain in the most painful knee (as defined by their highest
score on NRS or right side if equal, divided into three
groups at the lower and upper quartiles of the distribu-
tion 0 to 3, 4 to 7, 8 to 10); KL grade in the most painful
knee (≤1, 2, 3 or 4); presence of co-morbidities; and BMI
(<26, 26 to 30, >30).
A number of different measures of patient-reported
medication use were examined:
1. Any use of prescription analgesics (any; type
unspecified) in the month prior to assessment (yes/
no).
2. Frequent use (that is, on more than half of the
days) in the month prior to assessment (yes/no) of
a) traditional analgesics (acetaminophen, prescription
NSAIDs, OTC NSAIDs, coxibs, opioids) and/or b)
nutraceutical medications (glucosamine, chondroitin,
MSM, doxycycline or SAMe).
3. The total number of analgesic types (acetaminophen,
prescription NSAID, OTC NSAID, coxibs, opioid) used
frequently in the month prior to assessment.
4. The change in the use of analgesics at 36 months;
whether participants who were taking at least one
analgesic at baseline were still taking the same drug
types, whether they had switched or added drug types,
or had reduced the number of types they were taking.
5. Frequent use of medication for pain, aching or
stiffness at any point over 36 months of follow-up
(yes/no), the derivation of which included the inter-
vening annual assessments (12 and 24 months).
Multiple binary logistic regression models were used to
identify characteristics that were independently associated
at baseline with the odds of having used medication within
the past month and with the odds of having used pain
medication over 36 months of follow-up. Independent
variables were entered simultaneously into the model in
one block; in a second block interaction terms age*KL
grade; age*comorbidity; sex*pain; race*pain were entered
using backwards selection and were retained if P <0.05.
We focussed on these specific interactions since they have
previously been reported to be associated with pain
[30,31]. The specific interactions listed were determined
a priori; backwards selection was used to ensure that only
those which were significant were retained in the model,
thus maximising the accuracy and interpretability of the
results. A generalized linear model assuming a negative
binomial distribution and using a log link was also created
to identify factors associated with the number of prescrip-
tion or OTC analgesic types that participants reported
using frequently in the month prior to baseline.
Summaries of specific medication types are presented
to give an indication of whether similar trends were
observed for all analgesics and/or nutraceuticals. These
results are considered exploratory due to the small num-
bers of participants taking some types of medication, and
no formal analyses were performed to identify predictors
of use of individual medication types.
All statistical tests were two-tailed; family-wise Holm-
Bonferroni corrections for multiple comparisons were
made, separating baseline modelling of medication use
from 36-month changes; for multivariable models only the
overall significance of each model was included in the cor-
rection. Following correction the threshold for significance
testing at the 5% level was set to P = 0.05 at baseline and
P = 0.006 for changes at 36 months.
Results
Of the 1,390 subjects in the Progression cohort, 987 were
included in the baseline analysis and 806 in the longitudinal
analysis. Reasons for exclusion are presented in Figure 1.
The likelihood of data being incomplete was not related to
the majority of demographic and clinical variables; a slightly
higher proportion of non-white subjects were excluded due
to incomplete data at baseline (8.0% versus 2.2%). Non-
white subjects were not substantively more likely to have
incomplete data at follow-up (8.7% versus 7.3%) but were
slightly more likely to be lost to follow-up (14.1% versus
8.1%).
The study population (n = 987) were 55.9% female and
71.0% white; 89.5% of the non-white group were African-
American. Mean ± SD (range) age was 61.5 ± 9.0 (45 to
79) years and BMI was 30.3 ± 4.9 (18.2 to 48.7) kg/m2.
The majority of participants met the American College of
Rheumatology (ACR) definition for an OA diagnosis
which requires articular knee pain for most days of the
prior month, radiographic evidence of osteophytes on
joint margins and either crepitus on active motion, motion
stiffness less than 30 minutes duration or age more than
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38 years [32]. All had reported radiographic OA at screen-
ing and were aged >38, 864 [87.7%] stated that they had
experienced pain on most days during the previous month
and a further 8.7% recorded pain NRS scores greater than
2 units in their most painful knee in the previous month.
KL grade in the most painful knee was grade 2 in 38.3% of
subjects; grade 3 in 44.8% and grade 4 in 16.9%. The med-
ian (IQR) number of medications (taken for all indica-
tions) was 3.0 (2.0 to 5.0).
That some subjects in the OAI progression cohort had
KL grades <2 despite the radiographic inclusion criteria
is likely related to disagreement between the initial OAI
enrolment centre assessment and subsequent centralised
KL readings. The OAI have compared the individual
clinic radiographic readings against a blinded, centralised
reading of a randomly-selected subset and reported sub-
stantial but not perfect agreement (weighted Kappa 0.71
(0.63 to 0.79)).
Patterns of medication use at baseline
Medication use at baseline is summarised in Table 1. At
baseline two-thirds of subjects (673/987, 68.2%) had used
either a conventional analgesic (defined as OTC NSAID,
prescription NSAID, acetaminophen, prescription coxib
or opioid) or nutraceutical medication (glucosamine,
chondroitin, MSM, doxycycline or SAMe) for joint pain
or arthritis for more than half of the days in the month
prior to the visit. Non-prescription (OTC) NSAIDs were
the most commonly used analgesic, and the agent used
most commonly in isolation (63.0% of OTC NSAID
Figure 1 Flow chart outlining inclusion of participants into the study.
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users, 167/265). Few patients were using opioids (3.3%
compared with 6.5% of the patients excluded due to total
knee replacement). Only a small number of participants
had received an intra-articular injection of either steroid
or hyaluronan.
Subjects were not specifically asked whether they were
concurrently taking different medication types in the
month prior to assessment; however, if they reported
using two or more medication types for more than half
of the days of the month (deemed frequent use), we
inferred that these must have overlapped. The frequent
use of a combination of conventional analgesic therapies
in the month prior to enrolment was reported by 11.9%
of participants at baseline (24.8% of those using an
analgesic therapy). Combining analgesic therapies with
nutraceuticals was also commonly reported (21.0%; see
also Additional File 1, Table S1).
Of those who brought in or identified their specific med-
ications in a list, use of a gastroprotective agent was
reported by 11.2% (92/820) at baseline. Of the subjects list-
ing a prescription NSAID (63/820; 7.7%), a proton pump
inhibitor (PPI) or histamine (H2) receptor antagonist was
listed by 7.2% (6/83), most commonly omeprazole or
esomeprazole. Of those subjects who brought in or identi-
fied a coxib (95/820; 11.6%) amongst their prescription
medications at baseline, 34.9% (29/83) also listed a PPI. A
diagnosis of stomach ulcers or peptic ulcer disease was
reported by 27 subjects. No subjects with stomach ulcer
diagnosis reported use of prescription NSAIDs, five
reported coxib use of whom four also used a PPI, whilst
four reported OTC NSAID use with one also using a PPI.
Factors associated with medication use at baseline
Any use of prescription analgesics
Use of prescription analgesics was more likely in female
participants and in those with higher pain NRS scores but
none of the other demographic or clinical variables were
independently associated with prescription analgesic use
Table 1 Severity of symptoms and medications used during the month prior to assessment at baseline and 36 months
Variable Baseline
All patients
N = 987
Baseline
Followed up
N = 806
36 months
Followed up
N = 806
Pain NRS in most painful knee, mean ± SD 5.5 ± 2.4 5.4 ± 2.4 4.8 ± 2.8
Prescription analgesic used at any time 30.1% 29.4% 24.2%a
Prescription or OTC analgesic used frequentlyb 47.8% 47.9% 42.9%
Nutraceuticals used frequentlyb 41.3% 43.4% 36.0%a
Number of medications Analgesics 0: 52.2% 52.1% 57.1%
used frequentlyb 1: 36.0% 37.6% 33.3%
2: 9.9% 8.8% 7.8%
≥3: 1.9% 1.5% 1.8%
Nutraceuticals 0: 58.7% 56.6% 64.0%a
1: 4.1% 4.2% 4.1% a
2: 30.1% 31.5% 22.8% a
≥3: 6.8% 7.7% 9.1% a
Patient-reported medication use:
Acetaminophenb 13.5% 12.5% 14.4%
Prescription NSAIDsb 8.2% 8.1% 9.3%
OTC NSAIDsb 26.8% 26.7% 21.3%a
Coxibsb 10.2% 9.8% 4.7%a
Opioidsb 3.3% 3.0% 5.0%
Chondroitin and/or Glucosamineb 40.7% 42.9% 35.4%a
Other nutraceuticalb 8.6% 8.8% 10.2%
Intra-articular steroid injectionc 4.2% 4.3% 7.3%
Intra-articular hyaluronan injectionc 2.0% 1.7% 3.3%
Medications brought into visit or identifiedd: N = 820 N = 690 N = 690
Proton pump inhibitor/H2 antagonist 11.2% 9.4% 21.4%
NSAID 7.7% 6.6% 13.9%
Coxib 11.6% 9.3% 5.2%
NSAID + PPI (% of NSAID users) 7.2% (6/83) 9.4% (5/53) 26.0% (25/96)
Coxib + PPI (% of coxib users) 34.9% (29/83) 30.7% (23/75) 41.7% (15/36)
astatistically significant change from baseline; bfor more than ½ days in the previous month; cin the previous 6 months; din the previous month, brought in or
identified in list of medication; Coxibs, COX-II inhibitors; KL, Kellgren-Lawrence; OTC, over the counter; NSAID, non-steroidal anti-inflammatory drug; NRS,
numerical rating scale; PPI, proton pump inhibitor; SD, standard deviation.
Kingsbury et al. Arthritis Research & Therapy 2013, 15:R106
http://arthritis-research.com/content/15/5/R106
Page 5 of 12
(Tables 2 and 3). No interactions were found between pain
and sex or race, or between age and presence of comor-
bidities or KL grade. Descriptive results for specific medi-
cation types (Table 4) suggest the observed trends were
generally applicable to all prescription analgesics.
Frequent use of prescription or OTC analgesics
For frequent use of OTC or prescription analgesics the
trends were generally consistent with those found for pre-
scription analgesics (Tables 2 and 3). Frequent analgesic
use was more likely in women and in subjects with higher
pain NRS. No substantive interactions were found in this
model.
Inspection of the descriptive data for specific medication
types (Table 4) suggests that the lack of association
between analgesic use and age when all types were com-
bined together was not consistently observed for individual
analgesic types; while use of prescription NSAIDs appeared
to be less common in older patients, use of OTC NSAIDs
was relatively consistent across the age groups, and aceta-
minophen use was more common in older patients.
Women and participants with higher pain NRS scores
tended to use more types of prescription or OTC analge-
sics; no associations with race, age, KL grade, comorbidity
or BMI were found and there were no substantive interac-
tions (Table 3).
Frequent use of nutraceuticals
Frequent use of nutraceuticals was less likely in non-white
participants and in those with comorbidities, and was
more likely in those with KL grade 4 compared to KL
grade 2 (Table 3). Those older than 74 years were signifi-
cantly less likely to take nutraceuticals than those under
65. There was no evidence that gender, pain NRS or BMI
were substantively associated with nutraceutical use.
These trends were similar in participants taking glucosa-
mine and/or chondroitin and those taking the less com-
monly used nutraceuticals (Table 4).
Change in medication use over time
Changes at the cohort level
Compared to baseline, at 36 months there was a reduc-
tion in the number of participants using prescription
analgesics in the previous month (29.4% versus 24.2%;
McNemar’s P = 0.004) and reporting frequent use of
nutraceuticals (43.4% versus 36.0%; P <0.001), and fewer
nutraceuticals were being used (standardised statistic =
-3.71, P <0.001). Despite this, following correction for
multiple comparisons there was no statistically significant
reduction in the number reporting frequent use of any
analgesic(s) (P = 0.013) and the total number of analgesic
medication types used had not decreased significantly
(Wilcoxon signed rank standardised statistic = -1.69, P =
0.091) (Table 1). The frequency of acetaminophen and
prescription NSAID use remained at similar levels (aceta-
minophen, 12.5% versus 14.4%; prescription NSAIDs,
8.1% versus 9.3%). Reported use of OTC NSAIDs (26.7%
versus 21.3%; McNemar’s P = 0.004), coxibs (9.8% versus
Table 2 Medication use during the 30 days prior to baseline, according to baseline demographic and clinical factors
Medication type used within 30 days of baseline
Variable Analgesic(s) Nutraceutical(s)
n Prescription; any use reported Prescription or OTC; frequent use reported Frequent use reported
Sex Male 435 25.3%** 39.3%** 42.8%
Female 552 33.9%** 54.5%** 40.2%
Race White 701 28.7% 45.2%* 47.9%**
Non-white 286 33.6% 54.2%* 25.2%**
Age <65 594 29.6% 46.6% 40.9%
65 to 74 312 29.5% 48.7% 44.2%
>74 81 35.8% 53.1% 33.3%
KL grade 2 378 27.0% 43.9% 35.7%**
3 442 31.7% 50.0% 41.0%**
4 167 32.9% 50.9% 55.1%**
Pain NRS 0 to 3 233 22.7%** 32.6%** 47.6%*
4 to 7 535 29.5%** 47.9%** 41.7%*
8 to 10 219 39.3%** 63.9%** 33.8%*
Co-morb Absent 696 28.7% 45.8% 45.7%**
Present 291 33.3% 52.6% 30.9%**
BMI <26 129 27.1%* 44.2%** 48.8%**
26 to 30 381 26.2%* 42.3%** 45.4%**
>30 477 34.0%* 53.2%** 36.1%**
BMI, body mass index kg/m2; Co-morb, co-morbidity; KL, Kellgren-Lawrence; NRS, numerical rating scale; OTC, over the counter. Unadjusted comparison
significant at *P <0.05 or **P <0.01.
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Table 3 Baseline demographic and clinical factors associated with medication use at baseline; results of multivariable modelling
Outcome
Analgesic(s) Nutraceutical(s)
Baseline factor Prescription;
any use reported
Prescription or OTC;
frequent use reported
Prescription or OTC;
number of different types used
Frequent use reported
Female 1.5 (1.1 - 2.0), P = 0.010 1.8 (1.3 - 2.3), P >0.001 IR 1.4 (1.2 - 1.8), P = 0.001 1.2 (0.9- 1.6), P = 0.197
Non-white 1.0 (0.7 - 1.4), p = 0.891 1.0 (0.7 - 1.3), p = 0.908 IR 1.0 (0.8 - 1.2), P = 0.733 0.4 (0.3 - 0.6), P <0.001
Age reference reference reference reference
65 to 74 versus <65 0.9 (0.7- 1.3), P = 0.722 1.0 (0.8 - 1.4), P = 0.919 IR 1.0 (0.8 - 1.2), P = 0.669 1.0 (0.8 - 1.4), P = 0.922
>74 versus <65 1.4 (0.8 - 2.3), P = 0.224 1.4 (0.8 - 2.3), P = 0.197 IR 1.0 (0.7 - 1.5), P = 0.830 0.6 (0.3 - 0.9), P = 0.026
KL grade reference reference reference reference
3 versus 2 1.2 (0.9 - 1.7), P = 0.180 1.2 (0.9 - 1.7), P = 0.133 IR 1.1 (0.9 - 1.4), P = 0.375 1.3 (0.9 - 1.7), P = 0.108
4 versus 2 1.4 (0.9 - 2.1), P = 0.107 1.4 (1.0 - 2.1), P = 0.071 IR 1.3 (0.9 - 1.7), P = 0.147 2.2 (1.5 - 3.3), P <0.001
Pain NRS reference reference reference reference
4 to 7 versus 0 to 3 1.3 (0.9 - 1.9), P = 0.152 1.7 (1.2 - 2.4), P = 0.001 IR 1.3 (1.0 - 1.7), P = 0.070 0.9 (0.6 - 1.2), P = 0.496
8 to 10 versus 0 to 3 1.9 (1.2 - 2.9), P = 0.004 3.1 (2.1 - 4.7), P <0.001 IR 1.7 (1.3 - 2.4), P = 0.001 0.8 (0.5 - 1.2), P = 0.204
Co-morbidity 1.1 (0.8 - 1.5), P = 0.544 1.1 (0.8 - 1.5), P = 0.491 IR 1.1 (0.9 - 1.4), P = 0.337 0.6 (0.5 - 0.9), P = 0.005
BMI reference reference reference reference
26 to 30 versus <26 1.0 (0.6 - 1.6), P = 0.944 1.0 (0.7 - 1.5), P = 0.973 IR 1.0 (0.7 - 1.4), P = 0.868 0.9 (0.6 - 1.4), P = 0.686
>30 versus <26 1.3 (0.9 - 2.1), P = 0.205 1.4 (0.9 - 2.1), P = 0.152 IR 1.2 (0.9 - 1.7), P = 0.191 0.7 (0.5 - 1.1), P = 0.114
Number of subjects included 987 987 987 987
Overall model significance:
Likelihood ratio test
c2=30.3, df = 11, p = 0.001 c2=72.7, df = 11, p<0.001 c2=38.8, df = 11, p<0.001 c2=81.2, df = 11, p<0.001
Goodness-of-fit test:
Hosmer & Lemeshow
c2=2.3, df = 8, p = 0.970 c2=11.27, df = 8, p = 0.187 c2=564.6*, df = 975, p = 0.579 c2=2.6, df = 8, p = 0.955
*Pearson Chi-square goodness-of-fit; Values presented are odds ratio (95% CI) unless otherwise stated; bold type indicates statistical significance. BMI, body mass index kg/m2; IR, incident rate; KL, Kellgren-Lawrence;
NRS, numerical rating scale; OTC, over the counter.
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4.7%; P <0.001) and chondroitin and/or glucosamine
(42.9% versus 35.4%; P <0.001) was reduced. There was a
substantial increase in the use of gastroprotective agents
(9.4% versus 21.4%).
Changes at the level of the individual
Analysis of medication usage at an individual participant
level indicated that the majority of people who were using
medication at baseline had changed their medication type
during the three year observation period (Table 5),
although all of the participants who reported using an
analgesic at baseline also reported using at least one
analgesic at 36 months. Of those using a traditional
analgesic at baseline, approximately one-third reported
use of the same analgesic type at 36 months (ranging from
26.2% of baseline prescription NSAID users to 40.6% of
baseline acetaminophen users). Nutraceuticals were more
commonly continued, with 61.8% of participants using
chondroitin and/or glucosamine at baseline still reporting
use at 36 months. Of the 149 patients who reported using
chondroitin at each of the annual follow-ups between
baseline and 36 months, 99.3% also reported using gluco-
samine consistently over the same period. Changes in
analgesic and nutraceutical use over 36 months according
to demographic and clinical variables are presented in
Additional File 1, Tables S2 and S3.
Subjects who consistently used no pain medication
throughout follow-up
A total of 88 participants (10.9%) reported that they had
not used any form of medication for pain, aching or stiff-
ness for more than half the days of at least one month in
the preceding year at each annual follow-up visit up until
36 months. We investigated the predictors of ever using
any form of pain medication (not limited to prescription
or OTC analgesics) during the follow-up period. Female
subjects (OR 95% CI 1.2 to 3.2, P = 0.009) and those
with moderate (1.6 to 2.6, P = 0.090) or severe (1.8 to
Table 5 Change in medication use by individuals between baseline and 36 months
Proportion of baseline users (n/N)
Therapy type used in month prior to visit Used at both BL and 36 months Used at BL but not 36 months
Acetaminophen 40.6% (41/101) 59.4% (60/101)
Prescription NSAIDs 26.2% (17/65) 73.8% (48/65)
OTC NSAIDs 39.1% (84/215) 60.9% (131/215)
Coxibs 31.6% (25/79) 68.4% (54/79)
Opioids 29.2% (7/24) 70.8% (17/24)
Chondroitin and/or glucosamine 61.8% (214/346) 38.2% (132/346)
BL, baseline; Coxibs, COX-II inhibitors; NSAID, non-steroidal anti-inflammatory drug; OTC, over the counter.
Table 4 The proportions of participants using specific types of analgesics or nutraceuticals at baseline according to
demographic and clinical characteristics
Variable n A’phen Px NSAID OTC NSAID COXIB Opoids Gluco/chond Other nutra
Sex Male 435 8.3% 6.9% 25.7% 6.4% 1.4% 42.3% 9.0%
Female 552 17.6% 9.2% 27.7% 13.2% 4.9% 39.5% 8.3%
Race White 701 11.6% 8.0% 24.7% 11.7% 2.7% 47.4% 10.1%
Non-white 286 18.2% 8.7% 32.2% 6.6% 4.9% 24.5% 4.9%
Age <65 594 12.3% 10.1% 27.3% 9.3% 3.4% 40.1% 8.9%
65 to 74 312 14.1% 6.1% 26.3% 11.9% 3.2% 43.9% 8.3%
>74 81 19.8% 2.5% 25.9% 11.1% 3.7% 33.3% 7.4%
KL grade 2 378 12.4% 9.8% 22.2% 9.3% 3.7% 35.4% 7.1%
3 442 13.6% 7.5% 30.5% 9.5% 3.6% 39.8% 7.9%
4 167 15.6% 6.6% 27.5% 14.4% 1.8% 55.1% 13.8%
Pain NRS 0 to 3 233 6.9% 6.9% 19.7% 9.4% 0.4% 47.2% 7.7%
4 to 7 535 14.8% 6.9% 26.5% 9.7% 3.0% 41.7% 8.4%
8 to 10 219 17.4% 12.8% 35.2% 12.3% 7.3% 31.5% 10.0%
Co-morb Absent 696 10.1% 7.6% 27.2% 10.6% 2.7% 44.8% 9.9%
Present 291 21.6% 9.6% 26.1% 9.3% 4.8% 30.9% 5.5%
BMI <26 129 11.6% 9.3% 24.0% 8.5% 2.3% 48.8% 10.0%
26 to 30 381 9.7% 5.0% 24.9% 10.0% 1.6% 44.9% 9.7%
>30 477 17.0% 10.5% 29.1% 10.9% 5.0% 35.2% 7.3%
A’phen, acetaminophen; BMI, body mass index kg/m2; chond, chondroitin; Gluco, glucosamine; KL, Kellgren-Lawrence; NRS, numerical rating scale; NSAID,
non-steroidal anti-inflammatory drug; nutra, nutraceutical; OTC, over the counter; Px, prescription.
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12.0, P = 0.002) baseline pain were more likely to use
some form of pain medication (Table 6 and Additional
File 1, Tables S2 and S3). Patients whose pain remained
the same or worsened were more likely to take medica-
tion at some point during follow-up than those whose
symptoms improved beyond smallest detectable differ-
ence (SDD) (1.0 to 2.8, P = 0.043). The odds of using
pain medication were unchanged in participants 65- to
74-years old (0.5 to 1.3, P = 0.320) but were reduced to a
borderline-significant degree in those more than 74 years
old compared to those under 65 (0.2 to 1.0, P = 0.053).
Patients with BMI >30 were more likely to use some
form of medication than those with BMI <26 (1.2 to 4.7,
P = 0.010). There was some indication that participants
with KL grade 4 (1.0 to 4.3, P = 0.061) and those with
comorbidities (1.0 to 3.2, P = 0.066) were more likely to
use medication.
Discussion
In this analysis of a large cohort with symptomatic
radiographic knee OA, most people were using pharma-
cological therapies frequently. The most commonly used
traditional analgesics were OTC NSAIDs, acetamino-
phen and prescription NSAIDs; within the limitations of
this analysis, traditional analgesic use appeared to be in
line with the American College of Rheumatology (ACR)
guidelines which recommend the use of acetaminophen,
NSAIDs and tramadol as first-line therapies for knee OA
[15]. However the most commonly used overall therapy
was nutraceuticals, despite a lack of recommendations
for their use. Analysis of the medication types used by
individuals for their joint pain revealed a high rate of
change over three years, in line with previous reports
that patients frequently change or discontinue treatments
used for OA pain [33-35]. The relatively small proportion
of people using an NSAID or an opioid at baseline who
also reported use at 36 months may reflect a number of
issues, including inadequate pain relief, side effects and
clinician analgesic strategies (for example, switching
agents to prevent development of tolerance to an agent).
Notably, approximately two-thirds of participants using a
nutraceutical at baseline were still using it at 36 months.
Use of conventional analgesic combinations was uncom-
mon, although use of an analgesic with a nutraceutical
was reported by 21.0% of participants. Higher pain levels
were associated with increased use of prescription and
OTC analgesics.
Opioids were used infrequently. This is in contrast to a
recent US study of medication usage in OA patients
prior to total hip or total knee replacement, which
reported opioids as the most commonly used medication
[36]. Due to concerns about dependence and side effects,
Table 6 Results of a multiple binary logistic regression model for use of medication for knee pain.
Variable Ever used pain meds
Female 1.9 (1.2 - 3.2), P = 0.009
Non-white 1.2 (0.6 - 2.2), P = 0.671
Age P = 0.136
65 to 74 versus <65 0.8 (0.5 - 1.3), P = 0.320
>74 versus <65 0.5 (0.2 - 1.0), P = 0.053
KL grade P = 0.151
3 versus 2 1.3 (0.8 - 2.2), P = 0.262
4 versus 2 2.0 (1.0 - 4.3), P = 0.061
Pain NRS P = 0.007
4 to 7 versus 0 to 3 1.6 (0.9 - 2.6), P = 0.090
8 to 10 versus 0 to 3 4.6 (1.8 - 12.0), P = 0.002
Co-morbidity 1.8 (1.0 - 3.2), P = 0.066
BMI P = 0.021
26 to 30 versus <26 1.3 (0.7 - 2.5), P = 0.360
>30 versus <26 2.4 (1.2 - 4.8), P = 0.010
Pain NRS samea or worse 1.7 (1.0 - 2.8), P=0.043
Number of patients included 806
Overall model significance:
Likelihood ratio test
c2=53.4, df = 12, P <0.001
Goodness-of-fit test:
Hosmer & Lemeshow
c2=5.48, df = 8, P = 0.713
aor improved by less than 2 units; BMI, body mass index kg/m2; KL, Kellgren-Lawrence; NRS, numerical rating scale; OTC, over the counter. For categorical
variables the joint significance of the combined categories is presented in addition to the results for each category relative to the reference category. Values
presented are odds ratio (95% CI) of reporting use of any form of medication for pain, aching or stiffness in either knee at any time during the 36-month follow-
up period unless otherwise stated; values in bold type indicate statistical significance.
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particularly in older individuals, opioids are often
reserved for individuals with pain refractory to treatment
with other medications and/or non-pharmacologic inter-
ventions. Hence, the low use of opioids observed in this
study may reflect the relatively low pain scores in this
OA population and the less advanced nature of the dis-
ease compared to the pre-joint replacement population.
Although opioid use was slightly higher in the group
excluded from the study due to knee replacement, it was
still lower than that reported in previous studies [36].
The infrequent use of opioids may also reflect uncer-
tainty on the role of opioids in musculoskeletal disorders
and the lack of adequate training in these agents, as high-
lighted by a recent ACR Taskforce [37].
At 36 months there was a notable reduction in coxib
usage which may reflect the withdrawal of rofecoxib and
valdecoxib from the U.S. market. The decrease in coxib
use at 36 months is likely reflective of both changes in
medication availability and increasing awareness of toxi-
city during this period [24,26,38].
Use of gastroprotective agents with concomitant
NSAID therapy was low at baseline (7.2%) and a higher
incidence of gastroprotective agent use was seen in
coxib users (34.9%). Almost one-fifth of subjects with a
history of stomach ulcers reported coxib use (with
three-quarters of these also using a PPI) compared to
no reported use of prescription NSAIDs by subjects
with a history of stomach ulcers or peptic ulcer disease.
The high co-prescription of gastroprotective agents with
coxibs may reflect prescription of coxibs to patients at
higher risk of GI toxicity. At 36 months, use of gastro-
protection was increased and, although still low, the
proportion of NSAID users reporting use of gastropro-
tection was 3.5 times that at baseline. This could possi-
bly reflect the awareness of findings supporting the
cost-effectiveness of the addition of gastroprotective
agents to both NSAIDs and coxibs [39].
Although prescription or OTC analgesic use was no
more or less common in patients aged >74 when all drug
types were considered simultaneously, there were appar-
ently conflicting trends for specific analgesic types. There
was a reduction in prescription NSAID use, which may
reflect recent recommendations that oral NSAIDs should
not be prescribed for those older than 75 years or with
GI/CV risk [40]. This is in contrast to previous studies
suggesting a high rate of NSAID prescription in popula-
tions with high GI and/or CV risk [27]. However there
was an increase in acetaminophen use and, perhaps more
worryingly, no reduction in OTC NSAID use in this
population, suggesting that although practitioners may
be adhering to guidelines recommending that NSAIDs
are not prescribed to their older patients, these patients
are still obtaining over-the-counter NSAIDs. It is of note
that this group were more likely to report using no pain
medication at all during follow-up (18.0% versus 9.7% of
those less than 65 years old), which may reflect the toler-
ability and toxicity of current analgesic therapies.
Women were more likely to use prescription or OTC
analgesics and used a greater number of different types, in
line with previous reports which have found increased
general prescription medication use in women, particularly
those over the age of 65, compared to men. These studies
also found women more likely to take multiple prescrip-
tion medications in combination and more likely to take
analgesic medications [22]. Increased odds of medication
use may reflect reports of higher pain scores in women
compared to men [10] although in our analyses female sex
remained predictive of analgesic use even after controlling
for pain.
Previous studies have reported higher OA-related pain
scores in non-white study participants compared to
white participants. Having controlled for pain, there were
no differences observed in the reported use of analgesics;
however, non-white participants were significantly less
likely to use nutraceuticals than white participants.
Decreased use of expensive OTC products may reflect
differences in socio-economic status, with three times as
many non-white subjects in the cohort reporting a total
income <$25,000/year compared to white subjects (32.3%
versus 11.1%).
This study has a number of limitations. Some patients
had to be excluded from the analysis because their centra-
lised KL reading was missing and we could not therefore
confirm a diagnosis of radiographic OA. There was a
high rate of loss to follow-up and incomplete data at
36 months, although the majority of characteristics were
not associated with the likelihood of missing data or loss
to follow-up. With the exception of PPI use, all medication
use was self-reported. Although there was very good cor-
relation between the reported use of coxibs and the identi-
fication of coxib medications [see Additional File 1,
Methods], the correlation was much lower for prescription
NSAID use; more subjects reported use than brought in
or identified an NSAID. There were only a small number
of people more than 74 years old; therefore, caution must
be used in interpreting patterns of drug use in this group.
Conclusions
In summary, we found that people with knee OA used
pain medications frequently and generally in line with cur-
rent guidelines from the ACR. Use of opioid medications
was surprisingly low whilst the high frequency of medica-
tion change may indicate issues of lack of durability of effi-
cacy and lack of long-term tolerability associated with
conventional OA analgesics. The persistent use of OTC
NSAIDs in the older population is an area of concern,
given the enhanced risk of side effects and increased inci-
dence of comorbidities.
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Additional material
Additional file 1: A supplementary file containing. 1) Supplementary
methods containing details of the OAI database, ethical approval and
eligibility assessment, and OAI exclusion criteria. 2) Supplementary results
containing details of the robustness of patient reported medication use
and the combinations of medications used by participants. 3)
Supplementary Table S1 showing combinations of analgesics and
nutraceuticals taken by subjects at baseline. 4) Supplementary Table S2
showing changes in nutraceutical use at 36 months relative to baseline
according to demographic and clinical variables and change in pain. 5)
Supplementary Table S3 showing changes in analgesic medication use
over 36 months according to demographic and clinical variables and
change in pain.
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